Ranking Year:
# | Company Name | Region | Tech Topics | Total |
|---|
1 |  | Medicine,Health care,Fibrate, ...[+2] | Patent: 12 | |
2 |  | Medicine,Prefilled Syringe,Bionics, ...[+2] | Patent: 2 | |
3 | | Medicine | Patent: 2 | |
4 | | Antibiotics,Medicine | Patent: 2 | |
5 | | Drug,Medicine | Patent: 1 |
Top 5 Key Players companies in Imipenem
by Most Patent Filings in the South Korea in 2022
The Imipenem top 5 is Discovery PatSnap’ annual ranking of the top 5 Most Patent Filings Imipenem Key Players in the South Korea. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Imipenem (Primaxin among others) is an intravenous β-lactam antibiotic discovered by Merck scientists Burton Christensen, William Leanza, and Kenneth Wildonger in the mid-1970s. Carbapenems are highly resistant to the β-lactamase enzymes produced by many multiple drug-resistant Gram-negative bacteria, thus play a key role in the treatment of infections not readily treated with other antibiotics.
Page generation time:
Apr 27 2025